DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Canada ONLY.
Information about the NUVAXOVID®COVID-19 Vaccine (Recombinant protein, Adjuvanted)
NUVAXOVID® COVID-19 Vaccine (Recombinant protein, Adjuvanted) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
NUVAXOVID® COVID-19 Vaccine (Recombinant protein, Adjuvanted) vaccine has been issued marketing authorization in Canada with Terms and Conditions that need to be met by the Market Authorization Holder to ascertain the continued quality, safety and effectiveness of the vaccine.
Patients should be advised of the nature of the authorization. For further information for NUVAXOVID® COVID-19 Vaccine (Recombinant protein, Adjuvanted) vaccine please refer to Health Canada’s COVID-19 vaccines and treatments portal.
Drug Identification Number (DIN): 02543656
Report an Adverse Event (AE)
If you are concerned about an adverse reaction, it should be reported to Health Canada by:
- Visiting the web page on adverse reaction reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.
Product Quality Complaint
If you would like to report a complaint regarding the quality of a product, you can access the Health Canada product complaint form via this link: www.healthycanadians.gc.ca/apps/radar/MD-IM-0005.08.html
Contact Us
Toll free:
09:00 - 17:00
Monday - Friday
